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Herpes simplex virus as a model vector system for gene therapy peutic gene; the gene remains episomal and does not inte-
in renal disease. The past decade has been marked by significant grate into the host cell genome. Repeated applications
advances in the application of gene transfer into living cells of could overcome this problem but are limited by the im-animals and humans. These approaches have been tested in a
mune and inflammatory responses that the virus induces.few animal models of inherited and acquired renal diseases,
Adeno-associated virus (AAV), a parvovirus, offers sev-including carbonic anhydrase II deficiency [1] and experimental
glomerulonephritis [2, 3]. Gene transfer into proximal tubular eral advantages in that it lacks immunogenic viral pro-
cells has been successfully accomplished by intrarenal arterial teins, can efficiently transduce nondividing cells, and in-
infusion of a liposomal complex [4] or an adenoviral vector tegrates into the host genome at a specific site within[5]. Tubular cells from the papilla and medulla have been
human chromosome 19q [6]. The major disadvantages ofselectively transduced by retrograde infusion into the pelvi-
this system are the restricted insert size the vector cancalyceal system of an adenoviral vector containing a reporter
for -galactosidase [5]. Although the results of these initial accommodate (approximately 4.4 kB), difficulties in pro-
studies are promising, further studies to optimize viral vectors, ducing sufficient purified virus for gene therapy, and
maximize gene delivery, minimize side-effects, and develop loss of site-specific integration with recombinant vectorscell-specific and long-term regulated gene expression are criti-
developed for gene therapy. Chimeric viral vectors arecal to the success of gene therapy targeted to specific compart-
now being developed that incorporate the favorable at-ments of the kidney. Our recent efforts have focused on defin-
ing the cellular pathways responsible for viral entry and tributes of two different viral vectors.
infection into renal epithelial cells using herpes simplex virus HSV has received little attention in the arena of gene
(HSV) as a model vector. We anticipate that a solid understand- therapy for renal disease. Rather, the focus has been oning of the basic scientific principles underlying viral entry and
the use of HSV in suicide gene therapy of tumors andgene expression into specific populations of renal cells will
facilitate the design of successful therapeutic viral-based gene its role as a vector for delivery of genes to the nervous
transfer strategies. system. However, distinct advantages of HSV as a vector
suggest that further exploration of its potential role in
treating renal diseases is warranted. Possibly the greatestCANDIDATE VIRAL VECTORS
advantage of HSV as a vector is its large genome size
Optimal viral vectors for gene delivery should exhibit (approximately 150,000 bp), which could readily accom-
cell tropism for target cell type, high transduction effi- modate up to 30 to 40 kb of foreign genetic material
ciency, and little or no cytotoxicity and should elicit mini- [7, 8]. This would allow simultaneous delivery of multiple
mal or no immune response. Retroviruses permit efficient genes or a very large gene, which may be important in
and stable transduction. These vectors are advantageous
some disease states such as autosomal polycystic kidney
because they do not induce an immune response. How-
disease caused by mutations in the very large protein
ever, random integration of the delivered gene into divid-
polycystin 1 (approximately 460 kD), the product of the
ing cells raises concerns about possible insertional muta-
PKD1 gene [9, 10]. Moreover, HSV grows easily in cellgenesis and a risk of malignant transformation. In organs
culture and replicates to high titers (108 to 109), facili-with a low mitotic index, such as the mature kidney, retro-
tating production of sufficient stocks for therapeuticviral vectors may also have limited efficiency of transduc-
purposes. The virus is well characterized with a genometion. Adenoviral vectors can transduce a variety of cell
that is maintained as a concatemerized circular or lineartypes but are limited by transient expression of the thera-
episome in infected cells. HSV readily infects epithelial
cells, including renal tubular epithelia, as shown later in
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Two different approaches have been employed in the 2002 by the International Society of Nephrology
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development of HSV as a viral vector for gene delivery: HSV ENTRY INTO RENAL EPITHELIAL
CELL LINESrecombinant vectors and amplicons. Recombinant vec-
tors have deletions in one or more essential viral gene(s). Our studies focus on the potential role of HSV as a
These vectors are replication defective and can establish viral vector for gene therapy for renal diseases by investi-
a productive infection only on complementing cell lines gating how the virus attaches to and invades target renal
that express the corresponding deleted essential viral cells. Using Vero cells, a cell line derived from the kidney
gene(s) in trans. The duration of gene expression in renal of a normal adult African green monkey, the pathway
cells infected with such vectors and whether repeated of HSV-1 entry has been partially characterized. Briefly,
applications of such HSV vectors would be limited by invasion of Vero cells in culture by HSV requires binding
the immune response are not known. of virus to receptors on the cell surface, followed by
An alternative strategy is the HSV amplicon system. fusion of the virion envelope with the cell plasma mem-
This approach involves introducing the gene(s) of inter- brane. This process is complex and involves multiple
est into a plasmid containing the HSV origin of replica- interactions between viral envelope glycoproteins and
tion and packaging signal. This construct is then trans- cell surface components. The initial interaction is binding
fected into a cell line, which is superinfected with helper of viral envelope glycoproteins gC and/or gB to cell sur-
virus. The helper virus provides replication and packag- face HS [16–18]. The evidence includes the following
ing functions in trans, enabling the amplicon to be pack- key observations. Cells devoid of HS (but not other gly-
aged into mature viral particles. Several different helper cosaminoglycans) because of enzymatic treatment or ge-
viruses have been developed, and recent modifications netic mutation have greatly reduced the numbers of re-
have resulted in increased yields of packaged vectors ceptors for HSV binding. These cells are poorly infected
free of contamination from helper-virus [11]. Because by HSV but are unaltered in their susceptibility to other
HSV DNA replication occurs via a rolling circle mecha- viruses, such as vesicular stomatitis virus [19, 20]. Soluble
nism, amplicon vectors contain multiple copies of the heparin, which is structurally similar to HS, inhibits the
plasmid. Since these vectors contain no virus-encoded binding of HSV to cells [20]. In contrast, chondroitin sul-
genes, they have the potential to provide long-term gene fate, a different glycosaminoglycan, fails to inhibit viral
expression in transduced cells and to induce little or no binding or infection. The viral envelope glycoproteins
immune response. gC and gB bind selectively and independently to heparin-
Selection of an optimal viral vector system for a spe- sepharose columns under physiological conditions [16].
cific gene therapy should take into consideration the Deletion of gC alone, but not gB, reduces, but does not
features described previously here (for example, genome abolish, specific viral binding activity, whereas deletion
size, ability to infect dividing or nonmitotic cells, whether of both gC and gB abolishes viral binding [16, 17]. To-
DNA integrates or remains episomal, and propensity to gether, these results suggest that initial binding of HSV-1
induce a host cell response), as well as the pathway of to Vero cells is mediated principally by interactions of
viral entry. The importance of the latter has only recently viral envelope glycoprotein gC with cell surface HS moie-
been recognized and has been underscored by experi- ties. Thus, although gC is nonessential in cell culture,
ences with adeno-associated virus (AAV) vectors for viral vectors deleted for this glycoprotein would be pre-
cystic fibrosis replacement gene therapy. Recent studies dicted to exhibit reduced binding activity and efficiency
have shown that the apical surface of human airway of gene transduction.
epithelia is resistant to infection by AAV2, presumably Expression of HS proteoglycans is cell and tissue-type
because of a lack of sufficient heparan sulfate (HS) pro- specific and is developmentally regulated [21–25]. The
teoglycans on the apical surface, an important receptor HS chain consists of alternating residues of an amino sugar
for AAV2 binding and entry [12, 13]. This has led to a and a uronic acid. As the chains polymerize, they un-
focus on other serotypes of AAV, such as AAV5, which dergo various sulfation and epimerization reactions that
appear to adhere to cells in an HS-independent fashion. result in structurally quite heterogeneous sequences dif-
In addition, levels of transduction for recombinant AAV fering in sequence, chain length, and degree, extent, and
vectors vary depending on cell type, with poorly differen- pattern of sulfations. These structurally diverse sequences
tiated cells transducing more efficiently than well-differ- may be differentially expressed on various cell types
entiated epithelial cell types [13]. The efficiency of AAV- and on the apical or basolateral surfaces of polarized
mediated ex vivo gene transfer is limited to regions of epithelial cells. Knowledge of the specific HS sequence
epithelial injury and preferentially targets basal-like cells that serves as the receptor for initial viral attachment
[14, 15]. Together, these studies highlight the importance and its relative expression on target cells is critical to
of defining, at a molecular level, the pathway of entry the success of viral gene therapy.
for candidate viral vectors and testing viral vectors in Following the initial HS attachment step, glycoprotein
D (gD) binds to cellular coreceptors. Several candidateprimary culture systems.
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gD coreceptors have been identified, including a mem-
ber of the tumor necrosis factor (TNF) receptor family
called herpes virus entry mediator A (HveA), and two
members of the immunoglobulin superfamily, termed
HveB (nectin2) and HveC (nectin-1) [26–29]. Most re-
cently, a unique HS sequence has been shown to serve
as a HSV-1–specific gD coreceptor [30]. These different
gD coreceptors may be differentially expressed on vari-
ous cell types, and the redundancy of the coreceptors
may explain, in part, the diverse tropism of HSV. The
specific gD coreceptor expression on human renal epi-
thelial cells has not yet been characterized.
How the interactions of gC and gB with HS sequences
and gD with its coreceptors trigger penetration is not
known. Penetration is mediated by a pH-independent
fusion of the virion envelope with the cell plasma mem-
brane and requires the concerted action of gB, gD, and
hetero-oligomers of gH-gL [31].
We recently explored the possibility that binding of
virus to cell surfaces might trigger activation of a signal
transduction pathway and facilitate viral entry [32]. This
hypothesis emerged from the observations that other mi-
Fig. 1. Stimulation of cellular protein tyrosine phosphorylation aftercrobial receptor–ligand interactions trigger signal trans-
exposure to HSV-1. Vero cells were mock infected or exposed to 10duction pathways, candidate coreceptors for gD are linked
PFU/cell of HSV-1(17) for 5, 10, or 30 minutes. Cell lysates were
to these pathways, and the common role of HS is as a prepared and analyzed by immunoprecipitation with PY20-agarose
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Immunopre-receptor for growth factors (which act via signal trans-
cipitated proteins were detected by Western blotting with PY20, anduction pathways) and HSV. Using immunoprecipi-
anti-phosphotyrosine antibody (Transduction Laboratories, Lexington,
tation and Western blotting, we found that at least three KY, USA). Molecular weight standards are indicated on the left. The
bars on the right identify the three cellular proteins (p80, p104, andcytoplasmic Vero cell proteins become tyrosine phos-
p140) that are tyrosine phosphorylated after exposure to HSV-1.phorylated within five minutes after exposure to either
Adapted from Qie et al [32].
serotype of HSV (Fig. 1) [32]. However, no phosphoryla-
tion is detected when cells are exposed to a mutant virus
deleted in gL (but expressing gC, gB, and gD at the cell
surface), which presumably binds to HS and gD corecep- were prepared; this virus is phenotypically wild type but
genotypically gL deleted. The stock harvested from com-tors (discussed later here). Phosphorylation is restored
when the gL-deletion virus is grown on a complementing plementing gL-expressing 79VB4 cells (gift of P. Spear)
had a titer of approximately 109 pfu/mL on 79VB4 cells;cell line. These studies suggest that the interactions of
gC or gB with HS and gD with its coreceptor are not no plaques were detected on Vero cells. Changes in
[Ca2]i were measured in individually identified Verosufficient to induce activation of this pathway.
One possible mechanism that could explain how acti- cells (5 to 6 cells per experiment) by digital ratiometric
imaging (340 nm/380 nm); a calibration was performedvation of signal transduction pathways might facilitate
viral entry is through changes in intracellular Ca2 con- at the conclusion of each experiment with EGTA/AM
and ionomycin, according to standard methodology [34].centration ([Ca2]i) and alterations in actin microfila-
ments. To test this hypothesis, Vero cells were loaded with Results from a representative experiment are shown in
Figure 2A. Similar results have been obtained in 15 ex-fura-2-AM for 30 minutes, superfused in the loading cham-
ber with phosphate-buffered saline (PBS) for 15 minutes, periments, although there is individual cell variability
in the response. Exposure to HSV-1 results in a rapidand then exposed sequentially to PBS buffer or HSV-1
at a multiplicity of infection of 5 pfu/cell. For these stud- increase in [Ca2]i, which peaks within 40 seconds and
rapidly returns to baseline.ies, we selected a virus deleted in an essential viral gene,
gL, as a prototypic candidate viral vector for gene ther- To determine whether the physical binding of virus to
cells is sufficient to induce the changes in [Ca2]i, Veroapy. The viral strain HSV-1(KOS)gL86 is a generous
gift of P. Spear (Northwestern University, Chicago, IL, cells were loaded with the fura-2-AM dye and were ex-
posed to the KOS-gL86 virus that had been grown onUSA). The deletion of gL results in mutant virions that
can bind to cells but fail to penetrate [33]. For these studies, noncomplementing cells. This virus is both phenotypi-
cally and genotypically gL deleted. Virus harvested fromstocks of KOS-gL86 harvested from complementing cells
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Fig. 2. Effect of viral entry on intracellular
Ca2 ([Ca 2]i) in Vero cells. Cells were loaded
with the fluorescent Ca2 indicator fura-2, and
their fluorescence intensity ratios (340 nm/380
nm) were monitored before, during, and after
exposure to either PBS or virus. (A) Cells were
exposed to HSV(gL86) harvested from com-
plementing cells (phenotypically wild type)
and (B) to HSVgL86 harvested from Vero
cells, rendering the virus able to bind but un-
able to penetrate the cells.
noncomplementing Vero cells had a titer of103 pfu/mL ple, binding of human immunodeficiency virus type 1 to
on both Vero and 79VB4 cells, reflecting a low level of the CD4 molecule induces phosphatidylionistol-3-kinase
recombinants. The relative concentration of viral parti- [36, 37]. [Ca2]i also appears to play a role in Epstein-
cles was determined by comparing the optical densitome- Barr virus penetration and human cytomegalovirus cell
try of the gD band after sodium dodecyl sulfate-poly- fusion [38, 39]. We speculate that changes in [Ca2]i may
acrylamide gel electrophoresis and Western blotting, as play an important role in facilitating HSV viral envelope-
previously described [32]. Fura-2-treated cells were ex- cell fusion, perhaps through rearrangements of actin mi-
posed to equivalent particle numbers, and the [Ca2]i crofilaments. Understanding this pathway in human re-
was monitored. As shown in Figure 2B, there was no nal epithelial cells should facilitate the development of
increase in [Ca2]i following exposure of cells to noncom- optimal HSV vectors for gene therapy.
plemented virus. This suggests that binding alone is not
sufficient to induce changes in [Ca2]i.
Studies are currently ongoing to determine whether HSV ENTRY INTO HUMAN RENAL
influx of extracellular Ca2 and/or release of Ca2 from EPITHELIAL CELLS
endoplasmic reticulum stores serve as the source of in-
We have begun to elucidate the viral and cellular com-crease in [Ca2]i and the importance of this pathway in
ponents and pathways critical for HSV invasion of renalviral entry. [Ca2]i is required for fusion of a wide variety
epithelial cells. To validate whether the results obtainedof biological membranes, including the fusion of some
enveloped viruses with cell membranes [35]. For exam- in cell lines will be applicable to human cells and tissue,
Herold et al: HSV as vector for gene therapy S-7
Fig. 3. Human renal tubular epithelial cells are susceptible to HSV-1 infection. Conditionally immortalized human renal collecting duct cells were
infected overnight with serial dilutions of HSV-1(17)(dUTPase) from the apical (A) or basolateral (B) compartments. Monolayers were fixed and
permeabilized and stained for -galactosidase expression.
we are studying the pathway of HSV viral entry into spe- proteins and involves a signaling pathway associated with
cific populations of human renal tubular epithelial cells. an increase in [Ca2]i. HSV, a vector in which the large
We found that HSV-1 readily infects immortalized genome size would allow delivery of very large genes,
normal human renal tubular epithelial cells (Fig. 3). Con- such as those encoding PKD1, efficiently infects human
ditionally immortalized human renal proximal tubule renal epithelial cells. Further exploration of the mecha-
(PST), collecting tubule (CT), and thick ascending limb nisms mediating viral entry is critical to the development
(TAL) epithelia were plated on collagen-coated Trans- of optimal vectors to treat diseases unique to specific
well (Costar, Cambridge, MA, USA) membrane filters, renal epithelial cell types.
grown to 80% confluence in segment-specific media at
the permissive temperature 33C and transferred to 37C ACKNOWLEDGMENTS
for 10 days to maximize differentiation [40–42]. Cells This work was supported by grants from the National Institutes of
were infected with HSV-1[17] (dUTPase) virus, which ex- Health AI36318 (BCH), DK44833 (PW), DK50595 (PW), and DK-
38470 (LMS) and an American Heart Association Grant-in-Aid (LMS).presses the reporter gene -galactosidase under control
The authors gratefully acknowledge the technical assistance of Barbaraof a viral early immediate gene product (generous gift Bloswick and Beth Zavilowitz.
from E. Wagner, University of California, Irvine, CA,
Reprint requests to Betsy C. Herold, M.D., Box 1657 Mount SinaiUSA). Virus was added to either the apical or basolateral
School of Medicine One Gustave L. Levy Place, New York, New Yorkcompartments, and infectivity was monitored for 24 10029-6574, USA.
hours after inoculation by staining for -galactosidase E-mail: betsy_herold@mssm.edu
expression (Fig. 3) [32]. All three cell types were suscep-
tible to infection from both the apical or basolateral REFERENCES
surface. In preliminary studies, cells were more suscepti-
1. Lai LW, Chan DM, Erickson RP, et al: Correction of renal tubular
ble to HSV when exposed from the apical surface. Infec- acidosis in carbonic anhydrase II-deficient mice with gene therapy.
J Clin Invest 101:1320–1325, 1998tion was inhibited by soluble heparin, suggesting that
2. Imai E, Isaka Y: Strategies of gene transfer to the kidney. Kidneyvirus entry into these cells is HS dependent. Further
Int 53:264–272, 1998
studies are ongoing to explore the molecular basis for 3. Tsujie M, Isaka Y, Ando Y, et al: Gene transfer targeting intersti-
tial fibroblasts by the artificial viral envelope-type hemagglutinat-differences in susceptibility to apical and basolateral in-
ing virus of Japan liposome method. Kidney Int 57:1973–1980, 2000fection among the three cell types. It remains to be deter-
4. Lai LW, Moeckel GW, Lien YH: Kidney-targeted liposome-medi-
mined whether differences in apical and basolateral ex- ated gene transfer in mice. Gene Ther 4:426–431, 1997
5. Moullier P, Friedlander G, Calise D, et al: Adenoviral-medi-pression of HS receptors, gD coreceptors, or signaling
ated gene transfer to renal tubular cells in vivo. Kidney Int 45:1220–pathways correlate with susceptibility to infection.
1225, 1994
6. Kotin RM, Berns KI: Organization of adeno-associated virus
DNA in latently infected Detroit 6 cells. Virology 170:460–467, 1989
SUMMARY 7. Latchman DS: Herpes virus vectors for gene therapy in the nervous
system. Biochem Soc Trans 27:847–851, 1999The results of the investigations summarized in this
8. Latchman DS: Herpes simplex virus vectors for gene therapy in
article indicate that HSV entry into renal epithelial cell Parkinson’s disease and other diseases of the nervous system. J R
Soc Med 92:566–570, 1999lines triggers tyrosine phosphorylation of host cellular
Herold et al: HSV as vector for gene therapyS-8
9. Consortium EPKD: The polycystic kidney disease 1 gene encodes heparan sulfate proteoglycan glypican-1 in the developing rodent.
Dev Dyn 211:72–87, 1998a 14 kb transcript and lies within a duplicated region on chromo-
26. Geraghty RJ, Krummenacher C, Cohen GH, et al: Entry of alpha-some 16. Cell 77:881–894, 1994
herpesviruses mediated by poliovirus receptor-related protein 110. Peral B, San Millan JL, Ong AC, et al: Screening the 3 region
and poliovirus receptor. Science 280:1618–1620, 1998of the polycystic kidney disease 1 (PKD1) gene reveals six novel
27. Montgomery RI, Warner MS, Lum BJ, Spear PG: Herpes simplexmutations. Am J Hum Genet 58:86–96, 1996
virus-1 entry into cells mediated by a novel member of the TNF/11. Sun M, Zhang GR, Yang T, et al: Improved titers for helper virus-
NGF receptor family. Cell 87:427–436, 1996free herpes simplex virus type 1 plasmid vectors by optimization
28. Warner MS, Geraghty RJ, Martinez WM, et al: A cell surfaceof the packaging protocol and addition of noninfectious herpes
protein with herpesvirus entry activity (HveB) confers susceptibil-simplex virus-related particles (previral DNA replication enve-
ity to infection by mutants of herpes simplex virus type 1, herpesloped particles) to the packaging procedure. Hum Gene Ther 10:
simplex virus type 2, and pseudorabies virus. Virology 246:179–2005–2011, 1999 189, 1998
12. Duan D, Yue Y, Yan Z, et al: Polarity influences the efficiency 29. Whitbeck JC, Peng C, Lou H, et al: Glycoprotein D of herpes
of recombinant adeno associated virus infection in differentiated simplex virus (HSV) binds directly to HVEM, a member of the
airway epithelia. Hum Gene Ther 9:2761–2776, 1998 tumor necrosis factor receptor superfamily and a mediator of HSV
13. Zabner J, Seiler M, Walters R, et al: Adeno-associated virus entry. J Virol 71:6083–6093, 1997
type 5 (AAV5) but not AAV2 binds to the apical surfaces of 30. Shukla D, Liu J, Blaiklock P, et al: A novel role for 3-O-sulfated
airway epithelia and facilitates gene transfer. J Virol 74:3852– heparan sulfate in herpes simplex virus 1 entry. Cell 99:13–22, 1999
3858, 2000 31. Spear P: Entry of alpha-herpesviruses into cells. Semin Virol 4:
14. Bals R, Xiao W, Sang N, et al: Transduction of well-differentiated 167–180, 1993
airway epithelium by recombinant adeno-associated virus is limited 32. Qie L, Marcellino D, Herold BC: Herpes simplex virus entry
by vector entry. J Virol 73:6085–6088, 1999 is associated with tyrosine phosphorylation of cellular proteins.
Virology 256:220–227, 199915. Teramoto S, Bartlett JS, McCarty D, et al: Factors influencing
33. Hutchinson L, Browne H, Wargent V, et al: A novel herpesadeno-associated virus-mediated gene transfer to human cystic
simplex virus glycoprotein, gL, forms a complex with glycoproteinfibrosis airway epithelial cells: comparison with adenovirus vectors.
H (gH) and affects normal folding and surface expression of gH.J Virol 72:8904–8912, 1998
J Virol 66:2240–2250, 199216. Herold BC, WuDunn D, Soltys N, Spear PG: Glycoprotein C
34. Grynkiewicz G, Poenie M, Tsien RY: A new generation of Ca2of herpes simplex virus type 1 plays a principal role in the adsorp-
indicators with greatly improved fluorescence properties. J Bioltion of virus to cells and in infectivity. J Virol 65:1090–1098, 1991
Chem 260:3440–3450, 198517. Herold BC, Visalli RJ, Susmarski N, et al: Glycoprotein
35. Papahadjopoulos D, Nir S, Duzgunes N: Molecular mechanismsC-independent binding of herpes simplex virus to cells requires
of calcium-induced membrane fusion. J Bioenerg Biomembr 22:cell surface heparan sulphate and glycoprotein B. J Gen Virol
157–179, 199075:1211–1222, 1994 36. Briand G, Barbeau B, Tremblay M: Binding of HIV-1 to its re-18. Spear PG, Shieh MT, Herold BC, et al: Heparan sulfate glycosami- ceptor induces tyrosine phosphorylation of several CD4-associated
noglycans as primary cell surface receptors for herpes simplex proteins, including the phosphatidylinositol 3-kinase. Virology
virus. Adv Exp Med Biol 313:341–353, 1992 228:171–179, 1997
19. Shieh MT, WuDunn D, Montgomery RI, et al: Cell surface recep- 37. Dimitrov DS, Broder CC, Berger EA, Blumenthal R: Calcium
tors for herpes simplex virus are heparan sulfate proteoglycans. ions are required for cell fusion mediated by the CD4-human
J Cell Biol 116:1273–1281, 1992 immunodeficiency virus type 1 envelope glycoprotein interaction.
20. WuDunn D, Spear PG: Initial interaction of herpes simplex virus J Virol 67:1647–1652, 1993
with cells is binding to heparan sulfate. J Virol 63:52–58, 1989 38. Dugas B, Delfraissy JF, Calenda A, et al: Activation and in-
fection of B cells by Epstein-Barr virus: Role of calcium mobiliza-21. Perrimon N, Bernfield M: Specificities of heparan sulphate pro-
tion and of protein kinase C translocation. J Immunol 141:4344–teoglycans in developmental processes. Nature 404:725–728, 2000
4351, 198822. Velleman SG, Liu X, Eggen KH, Nestor KE: Developmental
39. Keay S, Baldwin BR: Evidence for the role of cell protein phos-regulation of proteoglycan synthesis and decorin expression during
phorylation in human cytomegalovirus/host cell fusion. J Gen Virolturkey embryonic skeletal muscle formation. Poult Sci 78:1619–
77:2597–2604, 19961626, 1999
40. Racusen LC, Wilson PD, Hartz PA, et al: Renal proximal tubular23. Hsueh YP, Sheng M: Regulated expression and subcellular local-
epithelium from patients with nephropathic cystinosis: Immor-ization of syndecan heparan sulfate proteoglycans and the synde- talized cell lines as in vitro model systems. Kidney Int 48:536–
can-binding protein CASK/LIN-2 during rat brain development. 543, 1995
J Neurosci 19:7415–7425, 1999 41. Wilson PD, Dillingham MA, Breckon R, Anderson RJ: Defined
24. French MM, Smith SE, Akanbi K, et al: Expression of the heparan human renal tubular epithelia in culture: Growth, characterization,
sulfate proteoglycan, perlecan, during mouse embryogenesis and and hormonal response. Am J Physiol 248:F436–F443, 1985
perlecan chondrogenic activity in vitro. J Cell Biol 145:1103– 42. Wilson P: In vitro methods in renal research, in Pediatric Nephrol-
1115, 1999 ogy (4th ed), edited by Barratt T, Avner E, Harmon W, Balti-
more, Lippincott Williams & Wilkins, 1999, pp 269–28125. Litwack ED, Ivins JK, Kumbasar A, et al: Expression of the
